Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo capsules given Clear all
Completed Phase 4 Interventional Results available

Combination Treatment Study for Memory Impairment and Depression

NCT01658228
View directory record Official record
Conditions
Depression, Mild Cognitive Impairment
Interventions
Donepezil, Placebo, Citalopram, Venlafaxine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 26, 2026, 11:57 PM EDT
Recruiting Early Phase 1 Interventional

HA35 Moderate Alcoholic Hepatitis (AH) Study

NCT05018481
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Sodium Hyaluronate, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults

NCT01052662
View directory record Official record
Conditions
Opioid Dependence
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 25 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Sep 26, 2026, 11:57 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Atomoxetine and Executive Function in PTSD

NCT06573970
View directory record Official record
Conditions
Posttraumatic Stress Disorder With Attention Defic
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 26, 2026, 11:57 PM EDT
Recruiting Phase 2 Interventional

Milk Thistle Clinical Trial in Pediatric NAFLD

NCT06477146
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
Milk thistle (MT), Placebo, Lifestyle Modification, Fibroscan
Drug · Behavioral · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
9 Years to 22 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 26, 2026, 11:57 PM EDT
Active, not recruiting Phase 4 Interventional

Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery

NCT04580472
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Cephalexin, Placebo capsules
Drug · Other
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets

NCT00417612
View directory record Official record
Conditions
Hypophosphatemia, Familial, Hyperparathyroidism
Interventions
Paricalcitol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
9 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

NCT01156571
View directory record Official record
Conditions
Atherosclerosis, Percutaneous Coronary Intervention, Acute Coronary Syndrome
Interventions
cangrelor P2Y12 (platelet) inhibitor, Clopidogrel - 300 or 600 mg (study arm), Clopidogrel 600 mg post cangrelor
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
11,145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Anderson, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers

NCT02454699
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
MBX400, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Phase 4 Interventional Results available

Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation

NCT00628394
View directory record Official record
Conditions
Cognition in Schizophrenia
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Lactobacillus Rhamnosus GG ATCC 53103 (LGG) in Healthy Volunteers

NCT00934453
View directory record Official record
Conditions
Healthy
Interventions
Lactobacillus rhamnosus GG ATCC 53103, Placebo
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Phase 2 Interventional

A Study Of The Effectiveness Of Wafermine Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy

NCT02541396
View directory record Official record
Conditions
Acute Pain
Interventions
Wafermine, Oxycodone, Placebo
Drug
Lead sponsor
iX Biopharma Ltd.
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 26, 2026, 11:57 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma

NCT00393796
View directory record Official record
Conditions
Bladder Cancer
Interventions
SUTENT, Placebo
Drug · Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Early Phase 1 Interventional

Antibiotics Prior to Mini-screw Implant Insertion

NCT03582605
View directory record Official record
Conditions
Inflammation at Mini-screw Insertion Site, Mobility, Mini-screw
Interventions
Amoxicillin, Placebo oral capsule
Drug
Lead sponsor
St. Louis University
Other
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Early Phase 1 Interventional

Baclofen Treatment of Ataxia Telangiectasia

NCT00640003
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Sep 26, 2026, 11:57 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05123703
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
Ocrelizumab, Ocrelizumab Placebo, Fingolimod, Fingolimod Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
10 Years to 17 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
10
States / cities
La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 26, 2026, 11:57 PM EDT
Not listed Phase 4 Interventional

EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone

NCT03781596
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Retrospective evaluation of endoscopy prior to study drug, Symptom Survey, Medication Compliance Phone Call, Endoscopy while on study drug, Fluticasone, Omeprazole, Placebo oral capsule
Diagnostic Test · Other · Drug
Lead sponsor
Claire Daniels
Federal
Eligibility
6 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Phase 1 Interventional

PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

NCT03665454
View directory record Official record
Conditions
Parkinson Disease
Interventions
PF-06412562, Standard of Care Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

NCT00605215
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Laquinimod, Placebo, Avonex®
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Phase 1 Interventional

Drug Discrimination in Methadone-Maintained Humans Study 3

NCT01068847
View directory record Official record
Conditions
Drug Dependence
Interventions
2-4 of the drugs listed below
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2013 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Phase 3 Interventional Results available

Effect of Omega-3 Fatty Acid on Cortical Function in ADHD

NCT01883817
View directory record Official record
Conditions
Attention Deficit Disorder
Interventions
DHA Omega-3, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
5 Years to 15 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Phase 2 Interventional

Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer

NCT00615940
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
WX-671, placebo
Drug
Lead sponsor
Heidelberg Pharma AG
Industry
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Sep 26, 2026, 11:57 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

NCT00531752
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
PF-03654746, Placebo capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Lafayette, California • Los Alamitos, California • Newport Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Sep 26, 2026, 11:57 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Gene by Medication Interaction to the Acute Effects of Alcohol

NCT01343628
View directory record Official record
Conditions
Alcohol-induced Cue-craving, Alcohol Sensitivity
Interventions
Placebo Comparator, Active Comparator: Atomoxetine, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Charlottesville/ Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2012 · Synced Sep 26, 2026, 11:57 PM EDT